BOSTON, Jan. 15, 2025 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2025 first quarter results on Wednesday, February 5th after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, February 5th at 5 pm Eastern Time. The earnings press release, accompanying earnings presentation, and financial data tables will be accessible prior to the conference call and webcast on the Investor Relations section of the Company's website at P ...

– Unaudited 2024 total revenue of approximately $814 million, exceeding guidance –– Four approval applications submitted to FDA in 2024 –– Global launch preparations underway for sepiapterin for PKU, a $1 billion market opportunity; CHMP opinion expected Q2 2025, U.S. approval decision in July 2025 –  – License and collaboration agreement with Novartis for PTC518 program closed – – PIVOT-HD data readout for PTC518 expected Q2 2025 –WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: ...

He also leads the investing group IPO Edge , which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to init ...

WARREN, N.J., Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PST / 2:15 p.m. EST.The presentation will be webcast live on the Events and Presentations page under the Investors section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recomme ...

文章核心观点 - 公司PTC在第四次工业革命中扮演重要角色，其软件解决方案在制造业中具有显著的增长潜力，尤其是在数字化转型和工业软件需求增长的背景下 [2][16][20] 行业背景 - 数字化转型支出预计从2022年的1.9万亿美元增长到2027年的3.9万亿美元，年复合增长率为16.2%，反映了对数字技术和工业软件的强劲需求 [1] - 第四次工业革命是指集成智能数字技术的新时代，这些技术在实时中迭代工作，极大受益于制造业，PTC的软件在其中起到关键作用 [16] - 前三次工业革命分别以蒸汽动力、电力和信息技术的引入为标志，第四次工业革命则以数字化技术的集成和迭代为核心 [10] 公司PTC的软件解决方案 - 公司的闭环数字线（closed-loop digital thread）是其软件的核心，通过在整个产品生命周期中收集和分析数据，从初始设计到制造、服务和处置，不断优化流程 [11][13] - PTC的软件包括计算机辅助设计（CAD）、产品生命周期管理（PLM）、物联网（IoT）、增强现实（AR）和软件生命周期管理（SLM），这些软件协同工作，提升制造效率和产品质量 [5][7][17] 公司PTC的增长前景 - 公司重新聚焦于核心终端市场，并在低利率环境下工业支出回升的预期下，有望在中长期内显著增长 [4] - 公司管理层正在重组业务，专注于五个关键行业垂直领域：工业产品、航空航天和国防、电子和技术、汽车制造、医疗技术和生命科学，以推动年度经常性收入（ARR）增长 [19] - 公司的年度经常性收入（ARR）是关键指标，持续的双位数增长表明其订阅软件、软件即服务（SaaS）和支持合同的强劲表现 [18] - 随着这些技术的广泛采用，PTC为制造业客户增加的价值将显著提升，公司未来多年将实现显著增长 [15]

- If approved, vatiquinone would be the first and only authorized therapy for children with FA -- PTC's fourth approval application submitted to FDA in 2024 -WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) to the U.S. Food and Drug Administration (FDA)."We are excited to have reached this important milestone in the developm ...

公司合作与产品发布 - PTC与微软和大众集团合作，共同开发Codebeamer Copilot，这是一款基于生成式人工智能的工具，旨在通过简化产品需求管理、测试、验证和发布流程，增强物理产品（如车辆）的软件开发[1][3] - Codebeamer Copilot（测试版）预计将于2025年初向部分客户推出[2] 产品与市场定位 - Codebeamer是PTC用于管理物理产品软件开发复杂性的可信平台，2023年大众集团采用Codebeamer以提高其品牌和车辆项目的软件开发效率和质量[3] - PTC强调生成式人工智能在帮助客户解决复杂问题和投资新兴市场（如高效开发软件定义车辆）中的重要性[4] - PTC提供一系列先进的数字技术，包括计算机辅助设计（CAD）和产品生命周期管理（PLM），这些技术共同革新了有形商品的工程、生产和维护[5] 战略与市场表现 - PTC持续与科技巨头合作，以应对不断变化的市场需求，推动各行业的创新、效率和竞争力[6] - 在最近一个季度，PTC的收入同比增长15%，达到6.27亿美元，主要由持续收入和永久许可证的稳定增长驱动[7] - PTC的股票在过去一年中上涨了25.9%，超过了其子行业的21.2%的增长[8]

Collaboration brings together industry leaders to advance generative AI use cases for manufacturing Codebeamer Copilot expected to simplify requirements management as part of the product development process Codebeamer Copilot beta expected to release in early 2025BOSTON, Dec. 3, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has partnered with Microsoft and Volkswagen Group to develop a generative artificial intelligence (AI) copilot based on the PTC Codebeamer® application lifecycle manage ...

Key TakeawaysShares of PTC Therapeutics soared Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.The deal gives Novartis global development, manufacturing, and commercial responsibility for PTC's experimental Huntington's Disease drug.PTC will receive $1.0 billion upfront, and said it would use the money to expand its splicing platform and increase its commercial and development portfolio moves. Shares of PTC Therapeutics (PTCT) soared 1 ...

On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington’s disease program, which includes related molecules.Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales.Also Read: FDA Grants Conditional Approval For PTC Therapeutics’ Gene Therapy As First Eve ...